Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population.
HER-2 positive breast cancer
cardiac markers
cardio-oncology
cardiotoxicity
trastuzumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jul 2022
10 Jul 2022
Historique:
received:
06
06
2022
revised:
05
07
2022
accepted:
09
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Trastuzumab-induced cardiotoxicity (TIC) can lead to early treatment discontinuation. The aim of this study was to evaluate: N-terminal brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), myoglobin, and selected biochemical and clinical factors as predictors of TIC. One hundred and thirty patients with HER2-positive BC receiving adjuvant trastuzumab therapy (TT) were enrolled. Measurement of cardiac markers and biochemical tests as well as echocardiography were performed prior to TT initiation and every three months thereafter. Cardiotoxicity leading to treatment interruption occurred in 24 patients (18.5%). While cardiotoxicity caused early treatment discontinuation in 14 patients (10.8%), the TIC resolved in 10 (7.7%) and TT was resumed. The most common complication was a decrease in left ventricular ejection fraction of more than 10% from baseline or below 50% (7.7%). In patients with TIC, there was no increase in the levels of NT-proBNP, myoglobin, and CK-MB. BMI, hypertension, ischemic heart disease, diabetes, age, cancer stage, type of surgery, use of radiotherapy, chemotherapy, and hormone therapy were shown to not have an effect on TIC occurrence. NT-proBNP, myoglobin, and CK-MB are not predictors of TIC. There is an ongoing need to identify biomarkers for TIC.
Identifiants
pubmed: 35884413
pii: cancers14143353
doi: 10.3390/cancers14143353
pmc: PMC9313458
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the National Science Centre (Poland)
ID : DEC-2013/09/B/NZ5/00764
Références
J Prev Med Public Health. 2008 Mar;41(2):84-91
pubmed: 18385548
Heart Fail Rev. 2021 Jul;26(4):919-935
pubmed: 33405000
Nat Rev Clin Oncol. 2020 Apr;17(4):233-250
pubmed: 31836877
Neth Heart J. 2018 Nov;26(11):521-532
pubmed: 30141030
Medicine (Baltimore). 2016 Nov;95(44):e5195
pubmed: 27858859
Mol Clin Oncol. 2019 Jan;10(1):37-42
pubmed: 30655975
Kardiol Pol. 2020 Feb 25;78(2):131-137
pubmed: 31995035
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
Curr Heart Fail Rep. 2012 Jun;9(2):117-27
pubmed: 22382639
Eur J Echocardiogr. 2006 Mar;7(2):141-6
pubmed: 15941672
J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):141-6
pubmed: 24534802
Cardiovasc Res. 2019 Apr 15;115(5):935-948
pubmed: 30689737
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Exp Oncol. 2007 Dec;29(4):309-13
pubmed: 18199989
Circ Heart Fail. 2016 Jan;9(1):e002661
pubmed: 26747861
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
Lancet. 2019 Jun 29;393(10191):2599-2612
pubmed: 31178152
Breast. 2020 Dec;54:106-113
pubmed: 32977298
J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305
pubmed: 22949432
Breast Cancer Res Treat. 2018 Apr;168(3):631-638
pubmed: 29280043
Kardiol Pol. 2021 Feb 25;79(2):139-146
pubmed: 33146505
J Clin Oncol. 2001 May 15;19(10):2746-53
pubmed: 11352968
Lancet. 2021 May 8;397(10286):1750-1769
pubmed: 33812473
Genes Dis. 2020 Dec 17;9(3):648-658
pubmed: 35782984
Pol Arch Intern Med. 2022 Apr 28;132(4):
pubmed: 35089680
Int J Mol Sci. 2022 Mar 04;23(5):
pubmed: 35269958
Cancer. 2018 May 1;124(9):1904-1911
pubmed: 29381193
BMC Cancer. 2015 Apr 11;15:267
pubmed: 25885598
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Clin Ter. 2008 Nov-Dec;159(6):449-52
pubmed: 19169607
Eur Cardiol. 2018 Aug;13(1):64-69
pubmed: 30310475
Kardiol Pol. 2011;69(5):520-30
pubmed: 21594854
J Card Fail. 2008 Jun;14(5):437-44
pubmed: 18514938
Future Oncol. 2013 Feb;9(2):179-81
pubmed: 23414468
Am J Cancer Res. 2020 Apr 01;10(4):1045-1067
pubmed: 32368385
Open Heart. 2021 Apr;8(1):
pubmed: 33863836
Cancer Sci. 2018 Feb;109(2):446-452
pubmed: 29247589
J Clin Oncol. 2010 Sep 1;28(25):3910-6
pubmed: 20679614
Exp Oncol. 2008 Jun;30(2):157-9
pubmed: 18566582
Eur J Breast Health. 2021 Jun 24;17(3):234-238
pubmed: 34263150
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Breast Cancer Res Treat. 2019 Feb;174(1):187-196
pubmed: 30506110
N Engl J Med. 1971 Dec 23;285(26):1441-6
pubmed: 5122894
Clin Chem. 2005 Aug;51(8):1405-10
pubmed: 15932966
J Clin Oncol. 2016 Sep 10;34(26):3157-65
pubmed: 27458291
Eur J Heart Fail. 2017 Jan;19(1):9-42
pubmed: 27565769